BVT2733

Known as: BVT.2733 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2012
01220032012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Brown adipose tissue (BAT) increases energy expenditure and is an attractive therapeutic target for obesity. 11β-Hydroxysteroid… (More)
Is this relevant?
2013
2013
Pharmacologic glucocorticoids (GCs) inhibit osteoblast function and induce osteoporosis. 11β-hydroxysteroid dehydrogenase type 1… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2013
Review
2013
OBJECTIVE Metabolic syndrome (MetS) and Cushing's syndrome share common features. It has been proposed that increased… (More)
Is this relevant?
2012
2012
BACKGROUND Inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is being pursued as a new therapeutic approach for… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
OBJECTIVE To investigate the mechanism of BVT.2733 on insulin resistance, by using diet-induced obese (DIO) mice model. METHODS… (More)
Is this relevant?
2008
2008
BACKGROUND A substantial body of evidence indicates that reduced plasma adiponectin levels may be key in the development of… (More)
  • table 1
Is this relevant?
2006
2006
The 11β-hydroxysteroid dehydrogenase type-1 inhibitor BVT.2733 lowers blood glucose and insulin in mutant mouse models of obesity… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) has been proposed as a new target for type 2 diabetes drugs. The aim… (More)
Is this relevant?